“Medicare (and insurance) will never cover GLP-1s for weight loss.”
What the evidence shows
For years Medicare was effectively barred by statute from paying for drugs used only for weight loss, which made "Medicare won't cover it" broadly accurate — it would cover semaglutide for diabetes or, later, to reduce cardiovascular risk, but not obesity by itself. That changed with a demonstration. Under the Medicare GLP-1 Bridge, CMS gives eligible Part D enrollees access to certain anti-obesity GLP-1s (all formulations of Foundayo and Wegovy, plus the Zepbound KwikPen) for a fixed $50 per month, running July 1, 2026 through December 31, 2027. Eligibility is gated by clinical criteria (for example, a BMI of 35 or higher, or lower BMIs paired with specific conditions like heart failure, uncontrolled hypertension, chronic kidney disease, prediabetes, or prior heart attack or stroke). KFF has estimated roughly 3.8 million beneficiaries could qualify. Separately, coverage in the commercial and Medicaid worlds exists but remains a patchwork that varies by plan and state.
What we still don’t know
This is a demonstration, not permanent policy, and what happens after 2027 is uncertain — the broader Part D obesity-coverage model (BALANCE) was delayed indefinitely, and the Bridge was extended only through the end of 2027. It's also not "free" or unlimited: the $50 copay doesn't count toward the Part D deductible or out-of-pocket maximum, low-income cost-sharing help doesn't apply, and enrollment numbers and long-term continuation aren't yet known. Commercial coverage remains inconsistent.
Why the claim misleads
"Will never cover" is now wrong as an absolute — a real Medicare pathway for weight-loss GLP-1s exists as of mid-2026. But it's just as misleading to swing the other way and imply Medicare now simply pays for Ozempic for anyone who wants to slim down. The honest version sits in the middle: coverage is expanding but conditional, temporary, eligibility-gated, and plan-dependent, so whether a specific person qualifies is something to check against the current CMS rules and their own plan, not to assume in either direction.
Graded by The Peptide Era · evidence, not hype